Automation & Robotics

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Mass spectrometry / NMR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

Tracking HTS Assay Development Time: Opportunity for improving drug discovery

Tracking HTS Assay Development Time: Opportunity for improving drug discovery By Dr Jennifer Hartigan, Cindy Liu and William Downey High throughput screening (HTS) assays are developed more quickly now due to advances in technology, improved liquid handling and sensitive detection, as well as increased communication between scientists in high throughput… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #RNA #Screening #Stem cells #Target validation

Fluorescence Lifetime: Finally picking up momentum!

Fluorescence Lifetime: Finally picking up momentum! By Dr John Comley Fluorescence lifetime (FLT) largely failed to make a significant inroad as a screening technology when it was first introduced nearly a decade ago, despite the fact that intrinsically it has many benefits, particularly in dealing with assay interferences. Market studies… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Overview of Companion Diagnostics in the Pharmaceutical Industry Part 2: Business models

Overview of Companion Diagnostics in the Pharmaceutical Industry Part 2: Business models. By Dr Stephen Naylor and Toby Cole There is an emerging consensus that the development of Companion Diagnostics appears to offer a set of tools to address many of the current problems that pharmaceutical companies must overcome. This in… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Metabolomics #Molecular medicine #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Target validation #Toxicology #Translational #Translational chemistry

Towards Unbiased Biomarker Discovery

Towards Unbiased Biomarker Discovery Dr Jens Hoefkens High-throughput molecular profiling technologies are routinely applied for biomarker discovery to make the drug discovery process more efficient and enable personalised medicine. The ability to find novel biomarkers rests on large-scale data generation and unbiased data analysis. Over the past decade, biomarker discovery… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Genetics #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Imaging #Immunology #Oncology #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology #Translational #Translational chemistry

Recent Advances in HCS Laser Scanning Cytometry

By Dr John Comley Laser scanning cytometers have matured over the past decade to meet the needs of end-users for higher throughput cell analysis, to access to previously difficult applications and to keep pace with the diversity of new fluorophores, validated high content screening (HCS) assay kits and reagents now… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Clinical trials #Drug development #Drug discovery #Drug targets #High Content Screening #Imaging #Immunology / Virology & Vaccines #Lead discovery #RNA #Sequencing #System biology #Systems biology #Translational #Translational chemistry

The Healthcare Industry’s Evolving Role in Translational Research an Opportunity for Competitive Advantage

The Healthcare Industry's Evolving Role in Translational Research an Opportunity for Competitive Advantage By Gregory Venters During the 20th century, medical research has observed enormous advances in basic science discovery, highlighted by the sequencing of the human genome. However, we have not witnessed a corresponding success in the widespread application… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genomics #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #System biology #Systems biology #Theranostics #Therapeutics #Toxicology

Overview of Companion Diagnostics in the Pharmaceutical Industry: Part 1

By Dr Stephen Naylor and Toby Cole In this article we describe the current state of Companion Diagnostics and its impact on the pharmaceutical sector, and the need for Companion Diagnostics in the drug discovery and development process. This perspective is augmented by a consideration of the development of Companion… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Regulatory #RNA #Screening #System biology #Systems biology #Target validation

Design Of Experiments: Useful statistical tool in assay development or vendor disconnect

Design Of Experiments: Useful statistical tool in assay development or vendor disconnect By Dr John Comley The use of design of experiments (DOE) in assay development (AD) has the potential to speed up assay optimisation (ie reduce assay development bottlenecks) and to facilitate a more thorough evaluation of assay variables. Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Nanomedicine / nanotechnology #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Innovations In Drug Discovery Technology

Innovations In Drug Discovery Technology By Dr Al Kolb Technology has been a major driver of advances in drug discovery. Automation, nanofluidics, imaging, software and assay technologies have played a major role in getting better data, faster. Is drug discovery at such an advanced state that further improvements are no… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Genomics #Lead discovery #Protein chemistry / Proteomics #RNA #Screening

Leveraging Research Informatics to Accelerate Drug Discovery

Leveraging Research Informatics to Accelerate Drug Discovery By Dr Anirban Ghosh and Siddharth Sawhney Research informatics has a vital array of tools which can advance the speed and success rate of drug discovery. This article discusses that if pharma companies want to benefit from these tools and are serious about… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Business #Chemical engineering #Chemistry #Clinical trials #Drug development #Isotope labelling #Mass spectrometry / NMR #Medicinal chemistry #Pharmokinetics #Preclinical #Regulatory #RNA #Target validation

Custom Carbon-14 Radiolabelling: Investing to meet new challenges

Custom Carbon-14 Radiolabelling: Investing to meet new challenges By Dave Roberts One consequence of an increasing demand from regulators for robust quantitative data on the behaviour of new drugs in man and for information on the fate of pharmaceuticals in the environment, has been an increase in demand for carbon-14… Read More

#Archive

#Academic #Analytical chemistry #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Gene therapy #High Content Screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Patent Law #Regulatory #RNA #Therapeutics #Translational #Translational chemistry

Singapore Strengthens Position as Leading Site for Biopharmaceutical R&D

Singapore Strengthens Position as Leading Site for Biopharmaceutical R&D By Kian-Teik Beh Globally, pharmaceutical and biotech companies are confronted by an impending patent cliff, while being challenged with declining research and development (R&D) productivity and the need to integrate multidisciplinary scientific capabilities.       Against this backdrop, Asia presents… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Maximising the impact of technologies on drug discovery through portfolio management

Maximising the impact of technologies on drug discovery through portfolio management By Charles S. Dormer, Dr Mark Beggs, Dr Lynn Brennan and Roanna London The opportunities to invest in new technologies in drug discovery are broad and extensive. Knowing where to place your investment and ensuring return on these investments… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Preclinical #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Multiplexing for biological relevance in high throughput screening

Multiplexing for biological relevance in high throughput screening By William P. Downey, Dr Jennifer Hartigan and Cindy Liu The multiplexed assay is a technique used increasingly in high throughput screening (HTS) labs to study the complex environment of a target, according to HighTech Business Decisions’ (HTBD) industry report High Throughput… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #PCR #RNA #Screening #Stem cells

1536 Plate Progress: Done deal but difficult transition?

By Dr John Comley After nearly 15 years of challenging maturity 1536 plate adoption (particularly in primary screening), finally appears to have taken hold. There is now available a broad range of 1536 plate types; an ever expanding variety of tools that make most assays types and profiling approaches doable… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Chemistry #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Pharmokinetics #RNA #Screening #Target validation #Therapeutics #Toxicology

Harnessing fragment-based drug discovery at CRT

Himarnessing fragment-based drug discovery at CRT By Dr Andrew P Turnbull and Dr Martin E Swarbrick In the past decade, fragment-based drug discovery (FBDD) has gained increasing popularity in the pharmaceutical industry as a powerful alternative and complement to traditional high-throughput screening (HTS) as a source of preliminary hits for… Read More

#Archive